封面
市场调查报告书
商品编码
1692312

头颈癌药物市场 - 全球产业规模、份额、趋势、机会和预测,按药物类别、配销通路、地区和竞争细分,2020-2030 年预测

Head and Neck Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球头颈癌药物市场价值为 19.5 亿美元,预计到 2030 年将达到 27.5 亿美元,预测期内的年复合成长率(CAGR) 为 6.11%。癌症仍然是全球面临的重大健康挑战,影响着全球数百万人的生活。在众多癌症类型中,头颈癌特别复杂且难以治疗。其包括在口腔、咽、喉、鼻窦和鼻腔中发展的肿瘤,会严重影响患者的生活品质,需要专门的治疗。全球头颈癌药物市场透过提供创新的治疗方案在解决这个医疗问题中发挥关键作用。这种癌症类型会影响上呼吸道和消化道的几个部分,包括口腔、喉咙、声带、鼻窦和唾液腺。已知的风险因素包括吸烟和饮酒、人类乳突病毒 (HPV) 感染以及接触各种化学物质和刺激物。

市场概况
预测期 2026-2030
2024 年市场规模 19.5 亿美元
2030 年市场规模 27.5 亿美元
2025-2030 年复合年增长率 6.11%
成长最快的领域 免疫疗法
最大的市场 北美洲

头颈癌药物市场由持续的研究和开发努力推动,旨在改善治疗效果和提高患者的生活品质。推动市场成长的关键因素是头颈癌发生率的上升,尤其是由于 HPV 感染导致的年轻族群。早期发现和有效治疗对于提高存活率至关重要。精准医疗、免疫治疗等医疗技术的进步,推动了标靶治疗和个人化治疗方案的发展,疗效更佳,副作用更少。手术、化疗和放射疗法等传统治疗方法正在被免疫疗法(例如检查点抑制剂)和标靶疗法(例如 EGFR 抑制剂)等新疗法所补充。

主要市场驱动因素:

头颈癌发生率不断上升

主要市场挑战:

高发病率

主要市场趋势:

技术进步

目录

第 1 章:产品概述

第 2 章:研究方法

第 3 章:执行摘要

第 4 章:COVID-19 对全球头颈癌药物市场的影响

第五章:全球头颈癌药物市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依药物类别(化疗​​、免疫疗法、标靶治疗)
    • 按配销通路(医院药房、零售药房、网路药房)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第六章:亚太地区头颈癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章:欧洲头颈癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章:北美头颈癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 墨西哥
    • 加拿大

第 9 章:南美洲头颈癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲头颈癌药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋头颈癌药物市场展望
      • 市场规模和预测
        • 按价值
      • 市场占有率和预测
        • 按药物类别
        • 按配销通路

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章:全球头颈癌药物市场:SWOT 分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章:竞争格局

  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Astrazeneca Plc.
  • Fresenius Medical Care AG & CO. KGAA
  • F.Hoffmann-la Roche Ltd.

第 16 章:策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 19779

The global Head and Neck Cancer Drugs Market was valued at USD 1.95 billion in 2024 and is projected to reach USD 2.75 billion by 2030, with a compound annual growth rate (CAGR) of 6.11% during the forecast period. Cancer remains a significant global health challenge, affecting millions of lives worldwide. Among the various cancer types, head and neck cancer is particularly complex and difficult to treat. It includes tumors that develop in the oral cavity, pharynx, larynx, paranasal sinuses, and nasal cavity, and can severely impact patients' quality of life, requiring specialized treatments. The global head and neck cancer drugs market plays a critical role in addressing this medical issue by providing innovative therapeutic solutions. This cancer type affects several components of the upper respiratory and digestive tracts, including the mouth, throat, voice box, sinuses, and salivary glands. Known risk factors include tobacco and alcohol use, human papillomavirus (HPV) infection, and exposure to various chemicals and irritants.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.95 Billion
Market Size 2030USD 2.75 Billion
CAGR 2025-20306.11%
Fastest Growing SegmentImmunotherapy
Largest MarketNorth America

The head and neck cancer drugs market is driven by ongoing research and development efforts aimed at improving treatment outcomes and enhancing patient quality of life. A key factor contributing to market growth is the rising incidence of head and neck cancer, particularly among younger individuals due to HPV infections. Early detection and effective treatment are essential for improving survival rates. Advances in medical technologies, such as precision medicine and immunotherapy, have led to the development of targeted therapies and personalized treatment plans, which are more effective and have fewer side effects. Traditional treatments like surgery, chemotherapy, and radiation therapy are being supplemented by newer options, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies (e.g., EGFR inhibitors).

Key Market Drivers:

Increasing Incidence of Head and Neck Cancer

Head and neck cancer is a complex group of diseases that affect the oral cavity, throat, larynx, and nasal passages. This type of cancer significantly impacts patients' quality of life and has been steadily increasing in incidence worldwide. According to Global Cancer Statistics, head and neck cancer ranks as the third most common cancer globally, with 1.46 million new cases and 487,993 deaths, accounting for 7.6% of all cancer cases and 4.8% of cancer-related deaths globally. This growing burden, coupled with advancements in cancer treatments, is driving demand for innovative therapies. The market for head and neck cancer drugs is anticipated to experience significant growth as the healthcare sector prioritizes cancer care and patients increasingly seek effective treatment options. Risk factors for head and neck cancer include tobacco and alcohol use, HPV infection, and certain dietary habits. While smoking rates have declined, leading to a decrease in cancers related to the larynx, the rise in oropharyngeal cancers linked to HPV infection remains a concern.

Key Market Challenges:

High Incidence Rates

One of the primary challenges faced by the head and neck cancer drugs market is the high incidence of the disease. With cancers affecting the mouth, throat, and larynx among the most prevalent globally, the increased number of cases places significant pressure on healthcare systems. This rising incidence fuels demand for more effective treatments and medications.

Key Market Trends:

Technological Advancements

Technological advancements are playing a pivotal role in improving the diagnosis, treatment, and prognosis of head and neck cancer. These innovations are not only enhancing patient outcomes but also stimulating market growth. High-resolution imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) allow healthcare providers to detect and assess head and neck cancers with greater accuracy, facilitating early detection and timely intervention. Additionally, advances in genomics and proteomics have led to the identification of specific biomarkers associated with head and neck cancer. Biomarker-based tests enable early diagnosis and help develop personalized treatment plans tailored to individual patients. Telemedicine has also revolutionized healthcare delivery, allowing remote consultations and pathology reviews. This is especially important for head and neck cancer, as it enables specialists to provide expertise and collaborate in underserved or remote regions.

Key Market Players:

  • Merck & Co., Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc.
  • Fresenius Medical Care AG & CO. KGAA
  • F. Hoffmann-La Roche Ltd.

Report Scope:

This report segments the Global Head and Neck Cancer Drugs Market into the following categories, in addition to providing insights into industry trends:

By Drug Class:

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America: United States, Canada, Mexico
  • Europe: France, United Kingdom, Italy, Germany, Spain
  • Asia Pacific: China, India, Japan, Australia, South Korea
  • South America: Brazil, Argentina, Colombia
  • Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section includes detailed analysis and profiles of major companies operating in the Head and Neck Cancer Drugs Market.

Available Customizations:

TechSci Research offers customization options for this market report, allowing adjustments based on specific company needs. Customization options include the profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Head and Neck Cancer Drugs Market

5. Global Head and Neck Cancer Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Chemotherapy, Immunotherapy, Targeted Therapy)
    • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Head and Neck Cancer Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Head and Neck Cancer Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. India Head and Neck Cancer Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Australia Head and Neck Cancer Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel
    • 6.3.4. Japan Head and Neck Cancer Drugs Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Class
        • 6.3.4.2.2. By Distribution Channel
    • 6.3.5. South Korea Head and Neck Cancer Drugs Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Class
        • 6.3.5.2.2. By Distribution Channel

7. Europe Head and Neck Cancer Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Head and Neck Cancer Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Germany Head and Neck Cancer Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Spain Head and Neck Cancer Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Head and Neck Cancer Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. United Kingdom Head and Neck Cancer Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. North America Head and Neck Cancer Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Head and Neck Cancer Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Mexico Head and Neck Cancer Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Canada Head and Neck Cancer Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel

9. South America Head and Neck Cancer Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Head and Neck Cancer Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Head and Neck Cancer Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Head and Neck Cancer Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Head and Neck Cancer Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Head and Neck Cancer Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Head and Neck Cancer Drugs Market Outlook
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Head and Neck Cancer Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Head and Neck Cancer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Merck & Co., Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
  • 15.2. Eli Lilly and Company
  • 15.3. Bristol-Myers Squibb Company
  • 15.4. Astrazeneca Plc.
  • 15.5. Fresenius Medical Care AG & CO. KGAA
  • 15.6. F.Hoffmann-la Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer